New emphasis on combining multiple drugs with proven cardiovascular benefits mirrors
Key Guidelines
New ESC guidelines recommend the use of combination therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) along with SGLT2i, rather than one or the other - as is currently recommended.
This change reflects the unmet need for cardiovascular risk reduction in patients taking GLP-1 RA - including
The guidelines' authors noted that a recent meta-analysis of major cardiovascular outcome trails found a pooled 10% hazard reduction in major adverse cardiac events (MACE; a composite of cardiovascular death, heart attack, and stroke) with SGLT2i treatment, and a 15% MACE hazard reduction with GLP-1 RA treatment.
'We have long believed that combining therapies can prove to be an effective strategy in reducing cardiovascular risk in the type 2 diabetes population and we are very encouraged to see that the ESC is emphasizing this combinatorial approach in their treatment guidelines,' said
BETonMACE2,
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective
Due to the extensive role for
Cardiology
Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the
About
Founded in 2001,
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.
Forward Looking Statements
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words 'believes', 'anticipates', 'plans', 'intends', 'will', 'should', 'expects', 'continue', 'estimate', 'forecasts', and other similar expressions. In particular, this news release includes forward looking information related BETonMACE, BETonMACE2, as well as to the potential role of apabetalone in the treatment of patients with cardiovascular disease, chronic kidney disease, post COVID-19 conditions, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Email: ir@resverlogix.com
Tel: 403-254-9252
Web: www.resverlogix.com
(C) 2023 Electronic News Publishing, source